On June 30, 2025, Akari Therapeutics Plc's shareholders approved an increase in shares available under the 2023 Equity Incentive Plan by 11 billion shares, reaching a total of approximately 19.8 billion ordinary shares. This significant decision supports the company’s incentive strategies and future growth plans.